Agenus (AGEN) vs Orchestra BioMed (OBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Agenus (AGEN) over the past year, gaining 107.3% versus a gain of 80.5%. Over five years, OBIO leads with a -39.6% price change compared with -92.6% for AGEN. Orchestra BioMed is the larger company by market cap ($357.6 million vs $346.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | OBIO |
|---|---|---|
| Share price | $7.67 | $5.95 |
| Market cap | $346.39M | $357.63M |
| 1-day change | +1.72% | +3.84% |
| YTD return | +144.27% | +43.37% |
| 1-year return | +80.47% | +107.32% |
| 5-year return | -92.64% | -39.59% |
| P/E ratio (TTM) | 3.03 | — |
| EPS (TTM) | $2.53 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $6.50 |
| 52-week low | $2.71 | $3.06 |
| Distance from 52-week high | -25.61% | -8.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +243.29% | +108.91% |
| Average volume | 4.26M | 300.90K |
| Shares outstanding | 45.16M | 60.11M |
| Employees | 81 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed AGEN by 26.8 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
AGEN vs OBIO FAQ
Which is bigger, Agenus or Orchestra BioMed?
Orchestra BioMed (OBIO) is larger, with a market capitalization of $357.63M compared with $346.39M for Agenus (AGEN).
Which stock has performed better over the past year, AGEN or OBIO?
OBIO returned +107.32% over the past 12 months, compared with +80.47% for AGEN (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Orchestra BioMed in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Agenus and Medicinal Chemicals and Botanical Products for Orchestra BioMed.